ONL Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$65M
- Investors
-
26
ONL Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to protect and improve patients' vision with various retinal diseases and conditions. The company develops therapeutics treatments for serious, vision-threatening retinal diseases and conditions with small-molecule peptides for the protection of photoreceptors in retinal detachment, enabling patients to have successful surgeries and improved outcomes.
Contact Information
Website
www.onltherapeutics.comCorporate Office
- 524 South Main Street
- Suite 110
- Ann Arbor, MI 48104
- United States
Corporate Office
- 524 South Main Street
- Suite 110
- Ann Arbor, MI 48104
- United States
ONL Therapeutics Timeline
ONL Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series D) | 16-Sep-2024 | $65M | Completed | Clinical Trials - Phase 2 | ||
| 9. Later Stage VC (Series C) | 12-Mar-2024 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series B) | 22-Dec-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 01-Aug-2020 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 01-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 12-May-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 15-Aug-2016 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 01-Sep-2014 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 01-Jan-2014 | Completed | Clinical Trials - Phase 1 | |||
| 1. Grant | 01-Jun-2012 | $400K | Completed | Clinical Trials - Phase 1 |
ONL Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C-2 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 1,013,962 | $0.000100 | $0.41 | $5.19 | $5.19 | 1x | $5.19 | 7.37% |
| Seed | 295,818 | $0.000100 | $0.4 | $4.97 | $4.97 | 1x | $4.97 | 2.15% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ONL Therapeutics Comparisons
Industry
Financing
Details
ONL Therapeutics Competitors (27)
One of ONL Therapeutics’s 27 competitors is PulseSight Therapeutics, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PulseSight Therapeutics | Venture Capital-Backed | Paris, France | ||||
| Kala Bio | Formerly VC-backed | Arlington, MA | ||||
| Gyroscope | Formerly VC-backed | London, United Kingdom | ||||
| SparingVision | Venture Capital-Backed | Paris, France | ||||
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA |
ONL Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ONL Therapeutics Patents
ONL Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230338470-A1 | Methods and compositions for treating ocular disorders with fasr | Pending | 26-Apr-2022 | ||
| EP-4456908-A1 | Sfasl for inhibiting rpe cell death and associated disorders | Pending | 27-Dec-2021 | ||
| US-20250163131-A1 | Sfasl for inhibiting rpe cell death and associated disorders | Pending | 27-Dec-2021 | ||
| AU-2022311780-A1 | Methods and compositions for improving visual function in ocular diseases and disorders | Pending | 13-Jul-2021 | ||
| EP-4370208-A2 | Methods and compositions for improving visual function in ocular diseases and disorders | Pending | 13-Jul-2021 | A61K38/10 |
ONL Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ONL Therapeutics Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Novartis Venture Fund | Corporate Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Mayewell Capital | Venture Capital | Minority | ||
| Visionary Venture Fund | Venture Capital | Minority | ||
| Bios Partners | Venture Capital | Minority |
ONL Therapeutics FAQs
-
When was ONL Therapeutics founded?
ONL Therapeutics was founded in 2011.
-
Where is ONL Therapeutics headquartered?
ONL Therapeutics is headquartered in Ann Arbor, MI.
-
What is the size of ONL Therapeutics?
ONL Therapeutics has 29 total employees.
-
What industry is ONL Therapeutics in?
ONL Therapeutics’s primary industry is Drug Discovery.
-
Is ONL Therapeutics a private or public company?
ONL Therapeutics is a Private company.
-
What is ONL Therapeutics’s current revenue?
The current revenue for ONL Therapeutics is .
-
How much funding has ONL Therapeutics raised over time?
ONL Therapeutics has raised $133M.
-
Who are ONL Therapeutics’s investors?
Novartis Venture Fund, , Mayewell Capital, Visionary Venture Fund, and Bios Partners are 5 of 26 investors who have invested in ONL Therapeutics.
-
Who are ONL Therapeutics’s competitors?
PulseSight Therapeutics, Kala Bio, Gyroscope, SparingVision, and Adverum Biotechnologies are some of the 27 competitors of ONL Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
